E. Witsch, M. Sela, and Y. Yarden, Roles for growth factors in cancer progression, Physiology (Bethesda), vol.25, issue.2, pp.85-101, 2010.

F. F. Barros, D. G. Powe, I. O. Ellis, and A. R. Green, Understanding the HER family in breast cancer: Interaction with ligands, dimerization and treatments, Histopathology, vol.56, issue.5, pp.560-572, 2010.

I. Lax, Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling, Mol Cell Biol, vol.8, issue.4, pp.1831-1834, 1988.

A. W. Burgess, EGFR family: Structure physiology signalling and therapeutic targets, Growth Factors, vol.26, issue.5, pp.263-274, 2008.

A. H. Clayton, Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis, J Biol Chem, vol.280, issue.34, pp.30392-30399, 2005.

T. P. Garrett, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha, Cell, vol.110, issue.6, pp.763-773, 2002.

Y. Yarden and M. X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, vol.2, issue.2, pp.127-137, 2001.

F. Shi, S. E. Telesco, Y. Liu, R. Radhakrishnan, and M. A. Lemmon, ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation, Proc Natl Acad Sci, vol.107, issue.17, pp.7692-7697, 2010.

B. S. Jaiswal, Oncogenic ERBB3 mutations in human cancers, Cancer Cell, vol.23, issue.5, pp.603-617, 2013.

G. Lurje and H. J. Lenz, EGFR signaling and drug discovery, Oncology, vol.77, issue.6, pp.400-410, 2009.

K. R. Schmitz and K. M. Ferguson, Interaction of antibodies with ErbB receptor extracellular regions, Exp Cell Res, vol.315, issue.4, pp.659-670, 2009.

M. Narayan, Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells, Cancer Res, vol.69, issue.6, pp.2191-2194, 2009.

J. T. Garrett, Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proc Natl Acad Sci, vol.108, issue.12, pp.5021-5026, 2011.

Y. Lu, Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab, Cancer Res, vol.67, issue.17, pp.8240-8247, 2007.

D. L. Wheeler, Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members, Oncogene, vol.27, issue.28, pp.3944-3956, 2008.

C. Desbois-mouthon, Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma, Clin Cancer Res, vol.15, issue.17, pp.5445-5456, 2009.

T. J. Kruser and D. L. Wheeler, Mechanisms of resistance to HER family targeting antibodies, Exp Cell Res, vol.316, issue.7, pp.1083-1100, 2010.

T. Ben-kasus, B. Schechter, M. Sela, and Y. Yarden, Cancer therapeutic antibodies come of age: Targeting minimal residual disease, Mol Oncol, vol.1, issue.1, pp.42-54, 2007.

D. A. Ferraro, Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR, Proc Natl Acad Sci, vol.110, issue.5, pp.1815-1820, 2013.

T. Ben-kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela, Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis, Proc Natl Acad Sci, vol.106, issue.9, pp.3294-3299, 2009.

L. M. Friedman, Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy, Proc Natl Acad Sci, vol.102, issue.6, pp.1915-1920, 2005.

D. Miles, Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA), Breast Cancer Res Treat, vol.142, issue.1, pp.89-99, 2013.

K. Gala and S. Chandarlapaty, Molecular pathways: HER3 targeted therapy, Clin Cancer Res, vol.20, issue.6, pp.1410-1416, 2014.

X. Chen, An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4, J Biol Chem, vol.271, issue.13, pp.7620-7629, 1996.

Y. Lazrek, Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation, Neoplasia, vol.15, issue.3, pp.335-347, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00815985

G. Thomas, HER3 as biomarker and therapeutic target in pancreatic cancer: New insights in pertuzumab therapy in preclinical models, Oncotarget, vol.5, issue.16, pp.7138-7148, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01075330

L. Aurisicchio, E. Marra, G. Roscilli, R. Mancini, and G. Ciliberto, The promise of antiErbB3 monoclonals as new cancer therapeutics, Oncotarget, vol.3, issue.8, pp.744-758, 2012.

J. Baselga and S. M. Swain, Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3, Nat Rev Cancer, vol.9, issue.7, pp.463-475, 2009.

N. Jiang, N. F. Saba, and Z. G. Chen, Advances in targeting HER3 as an anticancer therapy, Chemother Res Pract, p.817304, 2012.

A. Kol, HER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting, Pharmacol Ther, vol.143, issue.1, pp.1-11, 2014.

M. W. Pedersen, Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy, Cancer Res, vol.70, issue.2, pp.588-597, 2010.

J. A. Drebin, V. C. Link, and M. I. Greene, Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo, Oncogene, vol.2, issue.3, pp.273-277, 1988.

P. G. Kasprzyk, S. U. Song, D. Fiore, P. P. King, and C. R. , Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies, Cancer Res, vol.52, issue.10, pp.2771-2776, 1992.

F. Révillion, V. Lhotellier, L. Hornez, J. Bonneterre, and J. P. Peyrat, ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis, Ann Oncol, vol.19, issue.1, pp.73-80, 2008.

S. Khambata-ford, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, vol.25, issue.22, pp.3230-3237, 2007.

Q. Sheng, An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells, Cancer Cell, vol.17, issue.3, pp.298-310, 2010.

R. Dienstmann, Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC), J Clin Oncol, vol.31, p.3551, 2013.

J. Machiels, Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study, J Clin Oncol, vol.31, p.6002, 2013.

C. I. Spiridon, Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo, Clin Cancer Res, vol.8, issue.6, pp.1720-1730, 2002.

H. Waterman, A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling, EMBO J, vol.21, issue.3, pp.303-313, 2002.

X. Jiang, F. Huang, A. Marusyk, and A. Sorkin, Grb2 regulates internalization of EGF receptors through clathrin-coated pits, Mol Biol Cell, vol.14, issue.3, pp.858-870, 2003.

G. Levkowitz, Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1, Mol Cell, vol.4, issue.6, pp.1029-1040, 1999.

M. M. Sak, The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner, Carcinogenesis, vol.33, issue.5, pp.1031-1039, 2012.

H. Waterman, I. Sabanai, B. Geiger, and Y. Yarden, Alternative intracellular routing of ErbB receptors may determine signaling potency, J Biol Chem, vol.273, issue.22, pp.13819-13827, 1998.

Z. Cao, X. Wu, Y. L. Sweeney, C. Carraway, and K. L. , Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1, Mol Cell Biol, vol.3, issue.6, pp.2180-2188, 2007.

Z. Huang, The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling, Oncogene, 2014.

B. Jacobs, Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab, J Clin Oncol, vol.27, issue.30, pp.5068-5074, 2009.